Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial

To present the dosimetric results of a Phase II randomized trial comparing dose escalation to the MRI-defined dominant intraprostatic lesion (DIL) using either low-dose-rate (LDR) or high-dose-rate (HDR) prostate brachytherapy.

Source: Brachytherapy - February 19, 2019 Category: Cancer & Oncology Authors: Steven Tissaverasinghe, Juanita Crook, Francois Bachand, Deidre Batchelar, Michelle Hilts, Cynthia Araujo, Danielle Anderson, Terry Bainbridge, Brenda Farnquist Source Type: research